Through the establishment of our subsidiary, GenExosome Technologies Inc., as well as collaborations with Weill Cornell Medical College and Memorial Sloan Kettering Cancer Center, AVCO positions to become the foremost developer in the exosome technology domain, with focus in the following unmet diagnostic and therapeutic areas:
- Early detection of oral cancer (saliva exosomes)
- Early detection of ovarian cancer (plasma exosomes)
- Early detection of kidney cancer (urine exosomes)
- Skin regeneration and anti-fibrosis
- Treatments of degenerative disorders (Alzheimer’s disease, arthritis, osteoporosis.. etc.)
GenExosome Technologies Inc. (GT), a majority-owned subsidiary of AVCO, is a leading biotechnology company focused on the development of exosome-based diagnostic and therapeutic products. The Company was co-founded in the United States with Dr. Yu Zhou, a clinical scientist who has spent more than 10 years on exosome research and clinical utilization of exosomes products.
GT’s proprietary Exosome Isolation System has proven to be a cutting-edge technology, as its greatly enhances exosome isolation efficiency and exosome quality. Our innovative technology fosters the translation of exosome laboratory research into clinical advancement. Collaborating with world’s leading industrial and clinical partners, GT develops exosomes based diagnostic and therapeutic products, decode exosome carried bioinformatics and biobank exosome from body fluids.
GT has operation in New Jersey, Ohio in the USA and Beijing, Shanghai and Wuhan in China.